|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 乙型肝炎病毒母婴传播及其阻断研究的现状与存在问题显示文摘HBV可经血液、母婴、性接触等多种途径传播,其中母婴传播是我国HBV传播的主要途径之一.乙型肝炎母婴阻断是指通过产前、产时,产后采取一系列措施对新生儿进行保护以减少感染HBV机会的方法.近年来,HBV的母婴阻断取得了较好效果,总体阻断成功率约在90%以上,但仍有一定的失败率,在相关机制、方案优化等方面仍面临一些亟待解决的问题. | 邹怀宾 陈煜 张华 段钟平 李杰 庄辉 梁晓峰 Calvin Q.Pan | 2010 | 中华肝脏病杂志2010，18，7： | 18 |
| 2 | 查看详情显示文摘 | M.F.Shi Q.Pan Z.D.Min | | 0，，： | 1 |
| 3 | Hepatitis B virus X protein induces hypermethylation of p16<sup>INK4A</sup> promoter via DNA methyltransferases in the early stage of HBV‐associated hepatocarcinogenesis显示文摘 | Y.‐Z.Zhu R.Zhu J.Fan Q.Pan H.Li Q.Chen H.‐G.Zhu | 2010 | Journal of Viral Hepatitis2010，，2： | 1 |
| 4 | Optimal linear state estimator with multiple packet dropouts显示文摘 | Y.Liang T.W.Chen Q.Pan | | 0，，06： | 1 |
| 5 | Hepatitis B virus X protein induces hypermethylation of p16INK4A promoter via DNA methyltransferases in the early stage of HBV‐associated hepatocarcinogenesis显示文摘 | Y.‐Z.Zhu R.Zhu J.Fan Q.Pan H.Li Q.Chen H.‐G.Zhu | 2010 | Journal of Viral Hepatitis2010，，2： | 1 |
| 6 | The cullin protein family显示文摘 | Sarikas A T.Hartmann Z Q.Pan | | 0，，04： | 1 |
| 7 | Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir显示文摘 | C. Q.Pan K.‐Q.Hu A. S.Yu W.Chen C.Bunchorntavakul K. R.Reddy | 2012 | Journal of Viral Hepatitis2012，，3： | 1 |
| 8 | Risk assessment and management of hepatitis B reactivation from direct-acting antivirals for hepatitis C显示文摘Although hepatitis B virus(HBV)reactivation has been reported in hepatitis C patients who received interferon therapy,rare cases of HBV reactivation occur in the context of direct-acting antiviral(DAA)agent therapy for treatment of hepatitis C virus(HCV)infection.Recent studies observed that the reactivations were predominantly in hepatitis B surface antigen(HBsAg)positive patients,but reactivation can rarely occur in patients who are HBsAg negative and hepatitis B core antibody(HBcAb)positive.The severity of an HBV flare varies.In some cases,severe liver injury or fulminant hepatic failure may occur.HBV reactivation may occur regardless of HCV genotype and type of DAA regimens.The onset of HBV reactivation can range from 4 to 48 weeks after initiating DAA therapy.These patients may have undetectable levels of HBV deoxyribonucleic acid(DNA)prior to DAA treatment.Pre-emptive antiviral therapy for HBV should be considered in HBsAg-positive patients with high levels of viremia who are not receiving HBV treatment.If HBV DNA viral load is less than the guideline criteria for HBV treatment,one should consider pre-emptive HBV antiviral versus HBV DNA monitoring during DAA therapy.For patients who are HBsAg negative but HBcAb positive,close monitoring of serum alanine aminotransferase(ALT)levels during/post-treatment is highly recommended.The current review summarizes the recommendations of different society guidelines and discusses the appropriate management strategies in various patient profiles. | Maureen Whitsett David M.Feldman Calvin Q.Pan | 2019 | Liver Research2019，3，2： | 0 |
| 9 | 恩替卡韦抗病毒治疗的乙型肝炎失代偿期肝硬化患者并发症的再代偿显示文摘目的分析恩替卡韦抗病毒治疗后慢性乙型肝炎失代偿期肝硬化患者再代偿的发生情况。方法前瞻性纳入以腹水为首发表现的慢性乙型肝炎失代偿期肝硬化患者,接受恩替卡韦治疗120周,每24周对患者进行1次随访(包括临床终点事件、血液学及影像学指标等),根据Baveno VII标准计算再代偿率。计量资料组间比较采用Student t检验或Mann-whitney U检验;计数资料的组间比较采用χ^(2)检验或Fisher确切概率法。结果在入组的320例患者中,283例完成了120周的随访,其中92.2%(261/283)的患者实现了病毒学应答。(HBV DNA<20 IU/ml),治疗后患者的Child-Pugh评分和MELD评分明显改善[(8.33±1.90)分与(5.77±1.37)分,t=12.70,P<0.001;(13.37±4.44)分与(10.45±4.58)分,t=5.963,P<0.001]。在120周随访期间,14例患者死亡,2例接受肝移植,19例发展为肝细胞癌,11例发生食管胃底静脉曲张出血,4例发生肝性脑病;60.4%(171/283)的患者在120周内实现了临床再代偿(持续12个月未发生失代偿事件),56.2%(159/283)的患者实现了再代偿(持续12个月未发生失代偿事件且肝功能好转);基线MELD评分>15的患者积极抗病毒治疗后实现再代偿的概率高于基线MELD评分≤15的患者[67.6%(50/74)与52.2%(109/209),χ^(2)=5.275,P=0.029]。结论乙型肝炎失代偿期肝硬化患者抗病毒治疗可以显著改善预后,大部分患者(56.2%)可以实现再代偿,基线病情较重的患者实现再代偿的概率并不低于其他患者。 | 张婷 邓优 康海燕 向慧玲 南月敏 胡瑾华 孟庆华 房继莲 胥婕 王晓明 赵红 Calvin Q.Pan 贾继东 徐小元 谢雯 | 2023 | 中华肝脏病杂志2023，31，7： | 0 |
| 10 | Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis:A Systematic Review and Meta-analysis显示文摘Background and Aims:Decompensated cirrhotic patients with hepatitis C(HCV)are often under-represented in clinical trials.We aimed to evaluate pooled data on the efficacy and safety of sofosbuvir(SOF)-based regimens in these patients.Methods:We conducted a systemic review and meta-analysis by searching multiple databases for studies published from October 2010 to October 2020.Outcomes of interest were sustained virologic response(SVR)and safety of SOFbased regimens in decompensated HCV patients.Two reviewers independently performed the study selection and data extraction.Results:We included 33 studies that enrolled 5,302 HCV patients.The pooled SVR rate in decompensated patients with SOF-based regimens was 85.1%(95%CI:82.8–87.3).Patients on SOF/velpatasvir±ribavirin achieved a significantly higher SVR(91.0%,95%CI:87.7–93.9)than that of SOF/ledipasvir±ribavirin[(86.3%,95%CI:84.6–87.8);p=0.004],or on SOF/daclatasvir±ribavirin(82.4%,95%CI:78.2–86.2%;p<0.001).Adding ribavirin to SOFbased regimens(pooled SVR 84.9%,95%CI:81.7–87.9)did not significantly increase the SVR[83.8%(95%CI:76.8–89.8%;p=0.76)]in decompensated patients,which was also true in subgroup analyses for each regimen within the same treatment duration.However,adding ribavirin significantly increased the frequency of adverse events from 52.9%(95%CI:28.0–77.1)to 89.2%(95%CI:68.1–99.9)and frequency of severe events.The pooled incidence of hepatocellular carcinoma and case-fatality of decompensated patients were 3.1%(95%CI:1.5–5.0)and 4.6%(95%CI:3.1–6.3),respectively.The overall heterogeneity was high.There was no publication bias.Conclusions:The analysis found that 12 weeks of SOF/velpatasvir without ribavirin is the preferred therapy,with a significantly higher SVR compared with other SOF-based regimens in decompensated HCV patients. | Wenyan Zhang Jing Zhang Shan Tang Yali Liu Xiaofei Du Lixia Qiu Menglu Liu Haibin Yu Calvin Q.Pan | 2023 | Journal of Clinical and Translational Hepatology2023，11，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员